Active Implants LLC
Latest From Active Implants LLC
Active Implants announced the completion of patient enrollment in the VENUS randomized trial of the NUsurface meniscus implant for the treatment of persistent knee pain caused by injured or deteriorated meniscus tissue. Results of the VENUS and SUN trial, which has also completed enrollment, will support a de novo clearance from US FDA, which would make it the first artificial meniscus approved in the US. NUsurface already has a CE mark and the company is planning to start a limited commercial release outside the US in 2019.
Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Orthonika Ltd., a spin-out from Imperial College London, is developing TMR, which it describes as the first total knee meniscus replacement. The start-up's implant is based on a proprietary polymer substrate that mimics the structure and function of the healthy meniscus, and the attachment mechanisms to the bone.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Active Implants Corp.
- North America
- Parent & Subsidiaries
- Active Implants LLC
- Senior Management
Ted David, Pres. & CEO
J. Michael Keenan, VP, Admin. & CFO
Eran Linder-Ganz, PhD, VP, R&D
Adam Klyce, VP, Mktg.
- Contact Info
Active Implants LLC
Phone: (901) 762-0352
5865 Ridgeway Center Pkwy.
Memphis, TN 38120
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.